IFx-Hu2.0
NMSC 2019-01
Phase 1 mab completed
Quick answer
IFx-Hu2.0 for Merkel Cell Carcinoma is a Phase 1 program (mab) at TuHURA Biosciences, Inc./NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TuHURA Biosciences, Inc./NV
- Indication
- Merkel Cell Carcinoma
- Phase
- Phase 1
- Modality
- mab
- Status
- completed